Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intestinal microbiota in colorectal cancer treated with capecitabine or TAS-102
NL-OMON29314Recruiting
- Sponsor
- Maastricht University Medical Center+
- Start
- Mar 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label trial of capecitabine, trifluridine + tipiracil and bevacizumab in colorectal cancer (CRC) (3 arms), sponsored by Maastricht University Medical Center+. Primary endpoint: Radiologic response assessment. Started Mar 2017; status: recruiting.
02
Drugs
capecitabinetrifluridine + tipiracilbevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NL-OMON29314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON29314.